Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free FRX Stock Alerts

Fennec Pharmaceuticals (FRX) Competitors

Fennec Pharmaceuticals logo
C$15.29 +0.29 (+1.93%)
As of 09/23/2026 10:32 AM Eastern
Compare

FRX vs. MJN, CRON, CARA, GUD, and DHT.UN

Should you buy Fennec Pharmaceuticals stock or one of its competitors? Fennec Pharmaceuticals's main competitors and comparable companies include Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), Knight Therapeutics (GUD), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Fennec Pharmaceuticals compare to Cronos Group?

Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Cronos Group Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Cronos Group has lower revenue, but higher earnings than Fennec Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$59.22M9.05-C$800.44K-C$0.12N/A
Cronos GroupN/AN/AN/AN/AN/A

15.4% of Fennec Pharmaceuticals shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cronos Group has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cronos Group's return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-6.21% -13.34% 8.88%
Cronos Group N/A N/A N/A

Summary

Fennec Pharmaceuticals beats Cronos Group on 6 of the 8 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Cronos Group has a net margin of 38.95% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cronos Group's return on equity of 6.46% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-6.21% -13.34% 8.88%
Cronos Group 38.95%6.46%-3.73%

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$59.22M9.05-C$800.44K-C$0.12N/A
Cronos GroupC$179.09M9.90-C$32.78MC$0.1925.32

Fennec Pharmaceuticals has a beta of 3.722406, indicating that its stock price is 272% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.29991, indicating that its stock price is 30% more volatile than the broader market.

Cronos Group has a consensus price target of C$4.92, suggesting a potential upside of 2.22%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

15.4% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of Cronos Group shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Cronos Group Neutral

Summary

Cronos Group beats Fennec Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cara Operations?

Cara Operations (TSE:CARA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

15.4% of Fennec Pharmaceuticals shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Fennec Pharmaceuticals -6.21%-13.34%8.88%

Given Cara Operations' higher probable upside, equities analysts plainly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Fennec PharmaceuticalsC$59.22M9.05-C$800.44K-C$0.12N/A

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cara Operations Neutral
Fennec Pharmaceuticals Neutral

Summary

Fennec Pharmaceuticals beats Cara Operations on 6 of the 9 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Knight Therapeutics?

Fennec Pharmaceuticals (TSE:FRX) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Fennec Pharmaceuticals has a beta of 3.722406, suggesting that its stock price is 272% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, suggesting that its stock price is 129% less volatile than the broader market.

Fennec Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$59.22M9.05-C$800.44K-C$0.12N/A
Knight TherapeuticsC$547.31M1.81-C$30.73MC$0.1567.27

15.4% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Knight Therapeutics had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Knight Therapeutics Neutral

Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 5.85%. Given Knight Therapeutics' higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Fennec Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Knight Therapeutics has a net margin of 2.72% compared to Fennec Pharmaceuticals' net margin of -6.21%. Knight Therapeutics' return on equity of 1.91% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-6.21% -13.34% 8.88%
Knight Therapeutics 2.72%1.91%0.51%

Summary

Knight Therapeutics beats Fennec Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, DRI Healthcare Trust had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for DRI Healthcare Trust and 0 mentions for Fennec Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 0.51 beat Fennec Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company Overall Sentiment
DRI Healthcare Trust Positive
Fennec Pharmaceuticals Neutral

0.8% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 15.4% of Fennec Pharmaceuticals shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DRI Healthcare Trust has a beta of 0.365327, indicating that its share price is 63% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.722406, indicating that its share price is 272% more volatile than the broader market.

DRI Healthcare Trust has a net margin of 5.02% compared to Fennec Pharmaceuticals' net margin of -6.21%. DRI Healthcare Trust's return on equity of 2.06% beat Fennec Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
DRI Healthcare Trust5.02% 2.06% 4.22%
Fennec Pharmaceuticals -6.21%-13.34%8.88%

DRI Healthcare Trust currently has a consensus target price of C$25.60, indicating a potential upside of 41.20%. Given DRI Healthcare Trust's higher probable upside, research analysts clearly believe DRI Healthcare Trust is more favorable than Fennec Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

DRI Healthcare Trust has higher revenue and earnings than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than DRI Healthcare Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DRI Healthcare TrustC$172.34M5.79C$9.73M-C$0.80N/A
Fennec PharmaceuticalsC$59.22M9.05-C$800.44K-C$0.12N/A

Summary

DRI Healthcare Trust beats Fennec Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FRX vs. The Competition

Export
MetricFennec PharmaceuticalsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$536.17MC$12.60BC$7.31BC$12.84B
Dividend Yield2.02%2.63%2.52%6.27%
P/E Ratio-127.42792.28274.0840.36
Price / Sales9.05862.22638.219.35
Price / Cash11.6688.6477.8082.29
Price / Book12.4510.5910.474.69
Net Income-C$800.44KC$2.81BC$3.49BC$299.09M
7 Day Performance1.39%-0.11%-0.67%0.01%
1 Month Performance-1.29%-1.34%-3.17%-2.14%
1 Year Performance31.36%2.86%15.14%20.17%

Fennec Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FRX
Fennec Pharmaceuticals
N/AC$15.29
+1.9%		N/A+30.3%C$536.17MC$59.22MN/A10
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600
CRON
Cronos Group
1.2957 of 5 stars		C$4.67
-1.1%		C$4.92
+5.3%		+32.1%C$1.72BC$179.09M24.58610
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80
GUD
Knight Therapeutics
0.3685 of 5 stars		C$10.25
+0.2%		C$9.50
-7.3%		+67.1%C$1.01BC$547.31M68.33830

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel